Upregulation of PD‐L1 expression is considered a predictive marker for nivolumab monotherapy in cases of pretreated non‐Sq NSCLC,11 as well as in NSCLC cases treated using first‐line pembrolizumab5 and second‐line pembrolizumab.3 Here, CD274 is linked to non-small cell lung carcinoma.